Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Jump to

    • Biosimilars to lead growth; generics to be a small part: Biocon

    • Public health a worry; privatisation a must: Kiran Mazumdar Shaw

    • Trastuzumab marketing approval may come in 12-18 months: Biocon

    • Will scale up contract mfg; $200 mn capex for key arms: Syngene

    • Strong biologics performance boosted Q1: Biocon CMD Kiran Shaw

    • Pharma cos have increased focus on quality controls: Biocon CMD

    • Drug to treat eye disease won't hit mkt before 2-3 yrs: Biocon

    • FDI in pharma via automatic route a welcome step: Biocon

    • Biocon-Mylan to file 4 drug applications in FY17 under rev-share

    • US, Europe filings to drive Biocon growth: Kiran Mazumdar-Shaw

    • Biosimilar insulin Glargine to make $100 m from FY18: Biocon

    • Realisations from insulin biosimilar to start from FY17: Biocon

    • Insulin mfg deal with Mexican co PISA to aid US mkt shr: Biocon

    • EU approval for making Rosuvastatin a key milestone: Biocon

    • US API import ban applies only to one drug: Biocon CMD

    • NeoBiocon partners with Novartis for diabetes drug in UAE

    • Hedging protects co from currency volatility: Syngene's COO

    • 'There needs to be a serious rethinking on CBDT Proposal'

    • Will focus on capacity expansion, customer needs: Syngene

    • Eye 20% CAGR growth in future; expansion plans on: Syngene

    • Need clearer FII policy for India's novel start-ups: Biocon

    • Major progress in IPR policy, should roll out yr-end:Biocon

    • Rationalising products to become specialised player: Biocon

    • Syngene listing likely by July, may offload 10%: Biocon

    • Will get Syngene listed in FY16, to file DRHP in Q1: Biocon

    Advisory Alert:

    It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347